Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to determine immune response to authorised SARS-CoV-2 vaccines in MS patients by collecting clinical and serological data at centres across Germany

Next Previous
Trial Profile

A study to determine immune response to authorised SARS-CoV-2 vaccines in MS patients by collecting clinical and serological data at centres across Germany

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 13 Oct 2023 According to Results presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis, the study has closed for recruitment, but documentation of started vaccination cycles is ongoing.
  • 13 Oct 2023 Status changed to active, no longer recruiting, according to Results presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
  • 13 Oct 2023 Results (data cutoff date: 22 Mar 2023) presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top